Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Administration of Most Closely HLA-matched Multivirus-specific Cytotoxic T-Lymphocytes for the Treatment of EBV, CMV, Adenovirus, HHV6, and BK Virus Infections Post Allogeneic Stem Cell Transplant

Next Previous
Trial Profile

Administration of Most Closely HLA-matched Multivirus-specific Cytotoxic T-Lymphocytes for the Treatment of EBV, CMV, Adenovirus, HHV6, and BK Virus Infections Post Allogeneic Stem Cell Transplant

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 20 Jan 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Posoleucel (Primary)
  • Indications Adenovirus infections; Cytomegalovirus infections; Epstein-Barr virus infections; Human herpesvirus 6 infections; Polyomavirus infections
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms CHARMS
  • Sponsors AlloVir

    • Most Recent Events

    • 11 Jan 2023 Results published in the Clinical Cancer Research
    • 09 Jan 2023 According to an AlloVir media release, results rom this trial were presented at the 64th ASH Annual Meeting and Exposition 2022.
    • 03 Nov 2022 According to an AlloVir media release, data from the trial will be presented at the 64th American Society of Hematology (ASH) Annual Meeting. The presentation will include final efficacy and safety results as well as posoleucel expansion and persistence data.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top